S&P 500   3,351.56 (-0.16%)
DOW   27,809.73 (-0.33%)
QQQ   270.80 (+0.18%)
AAPL   109.82 (-0.47%)
MSFT   202.40 (-0.25%)
FB   257.06 (+0.88%)
GOOGL   1,489.71 (+0.18%)
AMZN   3,012.34 (+0.12%)
NVDA   499.00 (+0.09%)
TSLA   440.58 (+4.05%)
BABA   274.51 (-0.44%)
CGC   16.35 (-0.30%)
GE   7.01 (-0.57%)
MU   51.75 (+1.51%)
AMD   77.08 (+0.69%)
T   29.14 (+0.24%)
F   7.29 (+0.14%)
ACB   6.90 (+0.15%)
GILD   64.56 (-0.74%)
NFLX   470.00 (-0.04%)
DIS   130.48 (+0.20%)
BAC   25.22 (-0.51%)
BA   166.91 (-0.37%)
S&P 500   3,351.56 (-0.16%)
DOW   27,809.73 (-0.33%)
QQQ   270.80 (+0.18%)
AAPL   109.82 (-0.47%)
MSFT   202.40 (-0.25%)
FB   257.06 (+0.88%)
GOOGL   1,489.71 (+0.18%)
AMZN   3,012.34 (+0.12%)
NVDA   499.00 (+0.09%)
TSLA   440.58 (+4.05%)
BABA   274.51 (-0.44%)
CGC   16.35 (-0.30%)
GE   7.01 (-0.57%)
MU   51.75 (+1.51%)
AMD   77.08 (+0.69%)
T   29.14 (+0.24%)
F   7.29 (+0.14%)
ACB   6.90 (+0.15%)
GILD   64.56 (-0.74%)
NFLX   470.00 (-0.04%)
DIS   130.48 (+0.20%)
BAC   25.22 (-0.51%)
BA   166.91 (-0.37%)
S&P 500   3,351.56 (-0.16%)
DOW   27,809.73 (-0.33%)
QQQ   270.80 (+0.18%)
AAPL   109.82 (-0.47%)
MSFT   202.40 (-0.25%)
FB   257.06 (+0.88%)
GOOGL   1,489.71 (+0.18%)
AMZN   3,012.34 (+0.12%)
NVDA   499.00 (+0.09%)
TSLA   440.58 (+4.05%)
BABA   274.51 (-0.44%)
CGC   16.35 (-0.30%)
GE   7.01 (-0.57%)
MU   51.75 (+1.51%)
AMD   77.08 (+0.69%)
T   29.14 (+0.24%)
F   7.29 (+0.14%)
ACB   6.90 (+0.15%)
GILD   64.56 (-0.74%)
NFLX   470.00 (-0.04%)
DIS   130.48 (+0.20%)
BAC   25.22 (-0.51%)
BA   166.91 (-0.37%)
S&P 500   3,351.56 (-0.16%)
DOW   27,809.73 (-0.33%)
QQQ   270.80 (+0.18%)
AAPL   109.82 (-0.47%)
MSFT   202.40 (-0.25%)
FB   257.06 (+0.88%)
GOOGL   1,489.71 (+0.18%)
AMZN   3,012.34 (+0.12%)
NVDA   499.00 (+0.09%)
TSLA   440.58 (+4.05%)
BABA   274.51 (-0.44%)
CGC   16.35 (-0.30%)
GE   7.01 (-0.57%)
MU   51.75 (+1.51%)
AMD   77.08 (+0.69%)
T   29.14 (+0.24%)
F   7.29 (+0.14%)
ACB   6.90 (+0.15%)
GILD   64.56 (-0.74%)
NFLX   470.00 (-0.04%)
DIS   130.48 (+0.20%)
BAC   25.22 (-0.51%)
BA   166.91 (-0.37%)
Log in
NASDAQ:PHIO

Phio Pharmaceuticals Stock Forecast, Price & News

$2.34
-0.13 (-5.26 %)
(As of 09/18/2020 09:33 AM ET)
Add
Compare
Today's Range
$2.34
Now: $2.34
$2.44
50-Day Range
$1.95
MA: $2.38
$2.94
52-Week Range
$1.60
Now: $2.34
$20.02
Volume450 shs
Average Volume729,316 shs
Market Capitalization$13.53 million
P/E RatioN/A
Dividend YieldN/A
Beta2.36
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. The company has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.05 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHIO
CUSIPN/A
CIKN/A
Phone508-767-3861

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Book Value$8.59 per share

Profitability

Net Income$-8,910,000.00

Miscellaneous

Employees9
Market Cap$13.53 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$2.34
-0.13 (-5.26 %)
(As of 09/18/2020 09:33 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PHIO News and Ratings via Email

Sign-up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Phio Pharmaceuticals (NASDAQ:PHIO) Frequently Asked Questions

How has Phio Pharmaceuticals' stock price been impacted by Coronavirus?

Phio Pharmaceuticals' stock was trading at $2.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PHIO shares have decreased by 10.8% and is now trading at $2.47.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Phio Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Phio Pharmaceuticals
.

When is Phio Pharmaceuticals' next earnings date?

Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Phio Pharmaceuticals
.

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp (NASDAQ:PHIO) released its earnings results on Wednesday, August, 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.31.
View Phio Pharmaceuticals' earnings history
.

What price target have analysts set for PHIO?

1 analysts have issued 12-month price targets for Phio Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Phio Pharmaceuticals' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 61.9% from the stock's current price.
View analysts' price targets for Phio Pharmaceuticals
.

Are investors shorting Phio Pharmaceuticals?

Phio Pharmaceuticals saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 80,000 shares, a drop of 36.5% from the August 15th total of 126,000 shares. Based on an average daily volume of 441,300 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.4% of the shares of the company are sold short.
View Phio Pharmaceuticals' Short Interest
.

Who are some of Phio Pharmaceuticals' key competitors?

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Ocugen (OCGN), Delta Air Lines (DAL), Evofem Biosciences (EVFM), IBM (IBM), Milestone Pharmaceuticals (MIST), Nabriva Therapeutics (NBRV) and Novan (NOVN).

Who are Phio Pharmaceuticals' key executives?

Phio Pharmaceuticals' management team includes the following people:
  • Dr. Gerrit Dispersyn Ph.D., Dr. Med. Sc, Pres & CEO (Age 44)
  • Ms. Caitlin Kontulis, VP of Fin. & Admin. and Sec. (Age 33)

What is Phio Pharmaceuticals' stock symbol?

Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."

Who are Phio Pharmaceuticals' major shareholders?

Phio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.58%).
View institutional ownership trends for Phio Pharmaceuticals
.

Which institutional investors are buying Phio Pharmaceuticals stock?

PHIO stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..
View insider buying and selling activity for Phio Pharmaceuticals
.

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Phio Pharmaceuticals' stock price today?

One share of PHIO stock can currently be purchased for approximately $2.47.

How big of a company is Phio Pharmaceuticals?

Phio Pharmaceuticals has a market capitalization of $14.28 million and generates $20,000.00 in revenue each year. The company earns $-8,910,000.00 in net income (profit) each year or ($19.33) on an earnings per share basis. Phio Pharmaceuticals employs 9 workers across the globe.

What is Phio Pharmaceuticals' official website?

The official website for Phio Pharmaceuticals is phiopharma.com.

How can I contact Phio Pharmaceuticals?

Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at 508-767-3861 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.